Biomarker for detecting intestinal cancer or evaluating lung metastasis risk of intestinal cancer and application of biomarker
By combining serum SEMA3C and tissue SMYD3 detection, the problem of insufficient specificity and sensitivity in the diagnosis of colorectal cancer lung metastasis in existing technologies has been solved, enabling efficient early diagnosis and large-scale screening. In particular, the diagnostic accuracy of colorectal cancer lung metastasis has been improved through IHC and ELISA detection technologies.
Patent Information
- Application Number
- CN202512026246.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-30
- Publication Date
- 2026-03-20
AI Technical Summary
Current technologies lack simple and organ-specific biomarkers for the early diagnosis of colorectal cancer lung metastases, resulting in insufficient specificity and sensitivity in clinical diagnosis. Existing serum biomarkers such as CEA and CA199 have low diagnostic sensitivity and specificity, making it difficult to distinguish metastatic nodules from benign lesions.
Serum SEMA3C and tissue SMYD3 were used as a combination of biomarkers. The levels of SEMA3C and SMYD3 in serum and tissue were detected by IHC and ELISA techniques to differentiate patients with colorectal cancer lung metastases from patients with primary colorectal cancer and other benign lung diseases.
It improves the diagnostic sensitivity and specificity of colorectal cancer lung metastasis, with an AUC of 0.867, a sensitivity of 90.2% and a specificity of 70.7%. It is simple to operate and low in cost, suitable for large-scale screening, and has higher stability and accessibility, enabling early diagnosis of colorectal cancer lung metastasis.